Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | CPA1 | P15085 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686602 | 0.90 | CA1 (0.40) | CA1CA2DPP4DPP8DPP9 | |
| SCHEMBL18826564 | 0.82 | CA1 (0.40) | CA1CA2DPP4DPP8DPP9 | |
| SCHEMBL19455913 | 0.78 | — | — | |
| SCHEMBL26178358 | 0.78 | — | — | |
| SCHEMBL276458 | 0.78 | — | — | |
| SCHEMBL24777703 | 0.78 | — | — | |
| SCHEMBL23253011 | 0.78 | — | — | |
| SCHEMBL16409904 | 0.78 | — | — | |
| SCHEMBL6314501 | 0.76 | — | — | |
| SCHEMBL1114506 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160282672-A1 | LIQUID CRYSTAL DISPLAY AND METHOD OF MANUFACTURING THE SAME | TCL CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2016-09-29 | — | — | US | disclosed |
| CN-102132398-B | Self-aligned barrier layers for interconnects | HARVARD COLLEGE | 2015-01-28 | — | — | CN | disclosed |
| US-7511178-B2 | Hydroformylation of aqueous formaldehyde in the presence of a coordination catalyst preferably comprising rhodium dicarbonyl acetonylacetone and 2-phospha-2-icosyl-1,3,5,7-tetramethyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decane; hydrogenation of glycolaldehyde; catalyst selectivity; cost efficiency | SHELL OIL COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090012333-A1 | Hydroformylation of aqueous formaldehyde in the presence of a coordination catalyst preferably comprising rhodium dicarbonyl acetonylacetone and 2-phospha-2-icosyl-1,3,5,7-tetramethyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decane; hydrogenating glycolaldehyde; catalyst selectivity; cost efficiency | ALMEIDA LENERO KARINA QUETZALY | 2009-01-08 | — | — | US | disclosed |
| US-7449607-B2 | reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst comprising: a source of rhodium, and a ligand including a phospha-1,3,5,7-tetralkyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decyl group | SHELL OIL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070249871-A1 | reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst comprising: a source of rhodium, and a ligand including a phospha-1,3,5,7-tetralkyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decyl group | SHELL OIL COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1697291-A1 | PROCESS FOR PREPARING GLYCOLALDEHYDE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058788-A1 | PROCESS OF PREPARING GLYCOLALDEHYDE | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012333-A1 | Hydroformylation of aqueous formaldehyde in the presence of a coordination catalyst preferably comprising rhodium dicarbonyl acetonylacetone and 2-phospha-2-icosyl-1,3,5,7-tetramethyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decane; hydrogenating glycolaldehyde; catalyst selectivity; cost efficiency | H1-0, H1-2, H1-10 | CA1 211/4885CA2 415/4885DPP4 4517/4885 |
| US-20070249871-A1 | reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst comprising: a source of rhodium, and a ligand including a phospha-1,3,5,7-tetralkyl-6,9,10-trioxa-tricyclo[3.3.1.1{3,7}]-decyl group | PHOSPHO1, H1-2, H1-0 | CA1 89/4885CA2 118/4885DPP4 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.